Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours

BACKGROUND: Despite substantial improvements in childhood cancer survival, drug resistance remains problematic for several paediatric tumour types. The urgent need to access novel agents to treat drug-resistant disease should be expedited by pre-clinical evaluation of paediatric tumour models during...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Hussein, D, Holt, S V, Brookes, K E, Klymenko, T, Adamski, J K, Hogg, A, Estlin, E J, Ward, T, Dive, C, Makin, G W J
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2009
Soggetti:
Translational Therapeutics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2713707/
https://ncbi.nlm.nih.gov/pubmed/19491903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605100
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi